CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER
✉ Email this page to a colleague
All Clinical Trials for Urologic G In Plastic Container
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003930 ↗ | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 1999-09-01 | RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery. |
| NCT00003930 ↗ | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | Completed | Radiation Therapy Oncology Group | Phase 1/Phase 2 | 1999-09-01 | RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery. |
| NCT00132301 ↗ | Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma | Completed | Sanofi | Phase 3 | 2006-06-01 | VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy. |
| NCT00132301 ↗ | Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma | Completed | VA Office of Research and Development | Phase 3 | 2006-06-01 | VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Urologic G In Plastic Container
Condition Name
Clinical Trial Locations for Urologic G In Plastic Container
Trials by Country
Clinical Trial Progress for Urologic G In Plastic Container
Clinical Trial Phase
Clinical Trial Sponsors for Urologic G In Plastic Container
Sponsor Name
